ICCM stock gains on seeking FDA nod for cancer treatment (NASDAQ:ICCM)
seekingalpha.com
news
2022-10-19 13:23:21

koto_feja The shares of Israeli medical device maker IceCure Medical Ltd (NASDAQ:ICCM) added ~19% pre-market Wednesday after the company announced it submitted a regulatory filing to obtain FDA clearance for ProSense System to treat breast cancer. ProSense System is designed to destroy tumors through cryoablation (freezing). ICCM's De Novo Classification Request for the device is based on interim data from the ICE3 clinical trial targeted at low-risk breast cancer in patients who are at high risk of undergoing surgery.
